

NYRx, the Medicaid Pharmacy Program: Prior Authorization Update

On **February 26, 2026**, the New York State Medicaid Drug Utilization Review Board (DURB) recommended changes to NYRx, the Medicaid Pharmacy Program. The Commissioner of Health reviewed the DURB's recommendations and approved the following changes.

Effective **July 16, 2026**, the following Drug Utilization Review (DUR) program clinical criteria requirements will be implemented:

Topical Immunomodulators for the treatment of atopic dermatitis:

- Trial of a medium, high, or very high potency preferred topical corticosteroid.
- Prior authorization is required when a topical Janus kinase inhibitor and systemic immunomodulator are used concurrently.
- Quantity limits:
 - Ruxolitinib: 60 grams per month and 120 grams per year.
 - Delgocitinib: 30 grams per month and 60 grams per year.

Systemic Immunomodulators for the treatment of atopic dermatitis:

- Trial of a medium, high, or very high potency preferred topical corticosteroid or a preferred topical immunomodulator.
- Systemic Janus kinase inhibitors:
 - Trial of a medium, high, or very high potency preferred topical corticosteroid and a preferred systemic immunomodulator.

Doxepin Cream:

- Trial of a preferred topical corticosteroid or preferred topical immunomodulator.
- Quantity limits of 45 grams per month and 180 grams per year.

Topical Steroids:

- Low, medium, and high potency topical corticosteroids: a yearly limit of 12 claims, or 360 grams.
- Very high potency topical corticosteroids: a yearly limit of six claims, or 240 grams.

- Very high potency topical corticosteroids: an age edit to allow coverage for patients 12 years of age and older.

Neurokinin Receptor Antagonists:

- Trial of one hormone replacement therapy regimen, unless otherwise contraindicated.

For additional information about the DURB, providers should refer to the NYS Department of Health "Drug Utilization Review (DUR)" web page at:

https://www.health.ny.gov/health_care/medicaid/program/dur/index.htm.

For additional information regarding NYRx PA criteria, providers should refer to the *NYRx, the Medicaid Pharmacy Program Preferred Drug List*, located at:

https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf.

To review a list of preferred products that generally do not require a PA when prescribed according to FDA labeling (unless otherwise indicated), providers should refer to the *NYRx Preferred Drug Quick List*, located at: https://newyork.fhsc.com/downloads/providers/NYRx_PDP_quicklist.pdf.

For a complete list of drugs covered by NYRx, providers should refer to the *Medicaid Pharmacy List of Reimbursable Drugs*, located on the eMedNY "Medicaid Pharmacy List of Reimbursable Drugs" web page, at: <https://www.emedny.org/info/formfile.aspx>.

Electronic PA requests are now accepted by NYRx via CoverMyMeds®, located at:

<https://www.covermymeds.health/about>. Consider this option as an effective and efficient way to request a PA. PA requests can also be submitted by phone at 1-877-309-9493 or by fax at 1-800-268-2990 to the NYRx Clinical Call Center, available 24 hours a day, seven days a week. For additional information, providers should contact the NYRx Education & Outreach at NYRxEO@primetherapeutics.com.

For practitioner-administered drug *Clinical Criteria Worksheets*, prescribers and pharmacists should refer to the *New York State Medicaid Fee-for-Service Practitioner Administered Drug Policies and Billing Guidance*, located at:

https://www.health.ny.gov/health_care/medicaid/program/practitioner_administered/medicaid_ffs.htm.

Resources

Prime Therapeutics™ NYRx, the Medicaid Pharmacy Program website (<https://newyork.fhsc.com/>)

eMedNY website (<https://www.emedny.org/>)

New York State Department of Health "Welcome to NYRx, the Medicaid Pharmacy Program" web page (https://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm)

New York State Department of Health website (<https://www.health.ny.gov>)

Prime Therapeutics™ NYRx, the Medicaid Pharmacy Program "NYRx Education & Outreach" web page (<https://newyork.fhsc.com/providers/education-outreach.asp>)

Contact Information

The NYRx Education and Outreach Call Center is available by telephone at (833) 967-7310 or by email at NYRxEO@primetherapeutics.com, from 8 a.m. to 5 p.m. (ET), Monday through Friday, excluding holidays.

The NYRx Education and Outreach team hosts virtual office hours each week for stakeholders to ask questions about NYRx and care coordination. Prescribers and pharmacists should visit the Prime Therapeutics™ NYRx, the Medicaid Pharmacy Program “NYRx Education & Outreach” web page, located at: <https://newyork.fhsc.com/providers/education-outreach.asp>, for more information.